Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Updated Price for Dutch TTF Natural Gas Calendar Month Futures (NYMEX: ITTJ25). Charting, Price Performance, News & Related ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer Inc. has said it will discontinue development of its closely watched obesity pill, danuglipron, dealing a severe blow ...

Pfizer just pulled the plug on its daily weight-loss pill, danuglipron, after a clinical trial flagged a potential ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

Dividend-paying stocks have consistently attracted investor interest due to their long-term value. CNBC highlights this by ...

Pfizer will halt its development of a weight-loss drug that was being closely watched by investors, in a significant blow to the US pharmaceutical group. The company said on Monday that it would stop ...

Pfizer's (NYSE: PFE) shares have been southbound for the better part of three years, partly because it was unable to repeat ...